Praxis Precision Medicines (PRAX) Common Equity (2019 - 2026)

Praxis Precision Medicines' Common Equity history runs 8 years deep, the most recent figure standing at $1.4 billion for Q1 2026.

• In Q1 2026, Common Equity rose 221.02% year-over-year to $1.4 billion; the TTM figure through Mar 2026 stood at $1.4 billion (up 221.02% YoY), while the FY2025 annual figure was $878.1 million, up 97.13% from the prior year.
• Common Equity was $1.4 billion for Q1 2026 at Praxis Precision Medicines, up from $878.1 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $1.4 billion in Q1 2026 to a low of $64.5 million in Q1 2023.
• Historically, Common Equity has averaged $340.6 million across 5 years, with a median of $229.7 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Common Equity slumped 69.66% in 2022, then surged 539.38% in 2024.
• A 5-year view of Common Equity shows it stood at $76.1 million in 2022, then slipped by 8.46% to $69.7 million in 2023, then soared by 539.38% to $445.4 million in 2024, then surged by 97.13% to $878.1 million in 2025, then soared by 60.56% to $1.4 billion in 2026.
• The last three Common Equity figures came in at $1.4 billion (Q1 2026), $878.1 million (Q4 2025), and $343.5 million (Q3 2025), per Business Quant data.